Veeva Systems has outlined a Copenhagen summit program on AI and data in pharmaceutical commercial and medical work, putting planned applications in sales, content review and medical engagement on the agenda.
In an Oct. 29 announcement, Veeva said it expects more than 1,200 industry experts and over 100 sessions. The company says the event is exclusively for life sciences professionals. The figures are Veeva’s expectations for the event.
AstraZeneca is scheduled to discuss how health care professional access data can inform field sales targeting. Bristol Myers Squibb will cover agentic AI in medical, legal and regulatory review, with the session focused on speeding promotional-content approvals and improving productivity. BeOne’s presentation will examine whether conversational tools on pharmaceutical websites can surface obstacles affecting treatment access for clinicians and patients.
Veeva lists Roche and Grünenthal for a session on coordinating health care professional engagement across sales visits, digital interactions and events. Bayer and Servier are scheduled to discuss a trusted international data foundation intended to expand AI use and support better decisions across markets.
The current agenda names Astellas alongside Biogen and UCB for a session on using medical insights to guide strategy; Veeva’s announcement referred to a third biopharma without naming it. Veeva also lists Bayer, Novo and One MSL for a discussion of how increasing AI use by health care professionals may affect scientific engagement strategies.
The summit is scheduled for Nov. 18-19, 2026, in Copenhagen, Denmark. The announced sessions describe planned discussions and use cases.
